Mycenax Biotech

Mycenax Biotech operates as a contract development and manufacturing organization that provides biopharmaceutical services for drug development and production and has actively expanded its ADC capabilities. The company has shifted toward advancing technology platforms and building GMP plants to meet international standards, working from a base in biosimilars and new biopharmaceuticals. It acquired TPG biologics, adding protein gene engineering and cell line technology to its process development and GMP manufacturing experience.

Mycenax serves customers across Asia-Pacific, Europe and the United States through GMP-compliant facilities that provide manufacturing solutions from drug substance to drug product and have passed inspections by the EMA, PMDA and Health Canada. After inspections by multiple international regulatory authorities, the company entered the commercial manufacturing phase for marketed biologics.